Jul 24 2012
Durata Therapeutics (NASDAQ: DRTX) today announced the closing of its
initial public offering of 8,625,000 shares of common stock at a public
offering price of $9.00 per share, before underwriting discounts,
including 1,125,000 shares of common stock issued upon the exercise in
full by the underwriters of their option to purchase additional shares
at the public offering price, less the underwriting discount.
BofA Merrill Lynch and Credit Suisse Securities (USA) LLC acted as joint
book-running managers for the offering. RBC Capital Markets, LLC and
Wedbush PacGrow Life Sciences acted as the co-managers for the offering.
Source: Durata Therapeutics